Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Rijkevorsel – page 62

1 144 clinical trials in Rijkevorsel, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Rijkevorsel at a glance
1 144
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 144 trials in Rijkevorsel

Open in trial search

Study comparing carboplatin-cyclophosphamide versus paclitaxel with atezolizumab as first treatment for advanced triple negative breast cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:BOOG Study Center B.V.

Multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of tolDC for Patients with Relapsing Remitting and Progressive Multiple Sclerosis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Toldc
  • Sponsor:Antwerp University Hospital

Multiple sclerosis

Not recruiting

Study on Frexalimab for Adults with Nonrelapsing Secondary Progressive Multiple Sclerosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.

Hepatic cirrhosis

Not recruiting

Study of Resmetirom in Patients with Well-compensated Non-alcoholic Steatohepatitis (NASH) Cirrhosis to Evaluate Effects on Liver Health

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Resmetirom
  • Sponsor:Madrigal Pharmaceuticals Inc.

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Tolebrutinib
  • Sponsor:Genzyme Corp.

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Palbociclib
  • Sponsor:ABCSG GmbH

Study on Acalabrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients Without del(17p) or TP53 Mutation

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Acerta Pharma B.V.

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Pfizer Inc.

Breast cancer+1

Not recruiting

Study of Tucatinib and Ado-Trastuzumab Emtansine for Patients with Advanced HER2+ Breast Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Tucatinib
  • Sponsor:Seagen Inc.

Study on Long-Term Safety and Effectiveness of Ofatumumab for Patients with Relapsing Multiple Sclerosis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ofatumumab
  • Sponsor:Novartis Pharma AG

Study of Atezolizumab and Tiragolumab for Patients with Unresectable Esophageal Squamous Cell Carcinoma After Chemoradiotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.